Feasibility and safety of endoscopic ultrasound-guided liver biopsy to diagnose parenchymal liver disease: A multi-centre retrospective cohort study

Table 2 Primary and secondary outcomes, n (%)

Variable	Overall	FNA	FNB	P value
Diagnostic adequacy
Yes	43 (86.0)	22 (84.6)	21 (87.5)
No	7 (14.0)	4 (15.4)	3 (12.5)	0.77
Final histopathological diagnosis
MASLD	16 (32.0)	8 (30.8)	8 (33.3)	0.94
DILI	12 (24.0)	6 (23.1)	6 (25.0)
Hemosiderosis	2 (4.0)	1 (3.8)	1 (4.2)
AIH	5 (10.0)	3 (11.5)	2 (8.3)
PBC	3 (6.0)	1 (3.8)	2 (8.3)
PSC	1 (2.0)	1 (3.8)	0 (0)
Acute cellular rejection	1 (2.0)	0 (0)	1 (4.2)
Cholestasis	2 (4.0)	1 (3.8)	1 (4.2)
Sarcoid	1 (2.0)	1 (3.8)	0 (0)
Non-diagnostic	7 (14.0)	4 (15.4)	3 (12.5)
Complications	1 (2.0)	0 (0)	1 (4.2)	0.29
Post procedure pain	5 (10.0)	2 (7.7)	3 (12.5)	0.57
Fulfills EASL criteria
Yes	27 (54.0)	7 (26.9)	20 (83.3)	< 0.0001
No	23 (46.0)	19 (73.1)	4 (16.7)
Fulfills AASLD criteria
Yes	17 (34.0)	2 (7.7)	15 (62.5)	< 0.0001
No	33 (66.0)	24 (92.3)	9 (37.5)
Number of complete portal triads, mean (SD)	17.1 (14.6)	10.6 (9.6)	24.1 (15.9)	0.0006
Length of longest specimen (mm), mean (SD)	8.1 (8.0)	2.2 (0.80)	14.6 (8.4)	< 0.0001
Total specimen length (mm), mean (SD)	24.2 (23.8)	9.4 (6.4)	40.3 (25.4)	< 0.0001

AIH: Autoimmune hepatitis; DILI: Drug-induced liver injury; MASLD: Metabolic dysfunction-associated steatotic liver disease; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; FNB: Fine needle biopsy; FNA: Fine needle aspiration; EASL: European Association for the Study of Liver; AASLD: American Association for the Study of Liver Diseases.